Mid-term Business Plan 2027 Position we aspire to establish by 2033
We aim to establish ourselves as a Global Specialized Player by 2033.
With a focus on the Psychiatry & Neurology and Oncology as priority disease areas, Sumitomo Pharma Group (the “Group”) will contribute to the betterment of healthcare and fuller lives of people worldwide through diverse approaches, including pharmaceutical products, regenerative medicine/cell therapy, and non-pharmaceutical solutions. In other areas, too, the Group will leverage its assets to deliver value to patients. With this, the Group aims to establish itself as a Global Specialized Player (“GSP”) by 2033.
The basic strategy of the Mid-term Business Plan 2027 (FY2023-FY2027), which was formulated in April 2023, is to make a “qualitative transformation” of the business structure and business practices.
In the meantime, the Company will build a foothold for achieving renewed growth after the expiration of the exclusive marketing period for LATUDA® (atypical antipsychotic) in the U.S. and for establishing a position as a GSP.
Approach to 2033
Established position as a Global Specialized Player (GSP)
Psychiatry & Neurology and Oncology as Priority Disease Areas, contribute to the betterment of healthcare
and fuller lives of people worldwide through diverse approaches (pharmaceutical products, regenerative
medicine/cell therapy, and non-pharmaceutical solutions), thus establishing a unique position globally.
based on accumulated
Know-how acquired by
To be developed
Pursuit of optimal
Psychiatry & Neurology Area
Diverse approaches to innovate the
conventional treatment system
- Our core area
- Accumulated data, experience, and know-how
Distinguished products to innovate
- Carefully selected R&D pipeline
- Unique fundamentals for drug discovery
Deliver value to patients by
leveraging our assets
- Women’s health issues, urological diseases, diabetes
- Rare diseases, infectious diseases